https://scholars.lib.ntu.edu.tw/handle/123456789/557700
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Awad M.M. | en_US |
dc.contributor.author | Gadgeel S.M. | en_US |
dc.contributor.author | Borghaei H. | en_US |
dc.contributor.author | Patnaik A. | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.contributor.author | Powell S.F. | en_US |
dc.contributor.author | Gentzler R.D. | en_US |
dc.contributor.author | Martins R.G. | en_US |
dc.contributor.author | Stevenson J.P. | en_US |
dc.contributor.author | Altan M. | en_US |
dc.contributor.author | Jalal S.I. | en_US |
dc.contributor.author | Panwalkar A. | en_US |
dc.contributor.author | Gubens M. | en_US |
dc.contributor.author | Sequist L.V. | en_US |
dc.contributor.author | Saraf S. | en_US |
dc.contributor.author | Zhao B. | en_US |
dc.contributor.author | Piperdi B. | en_US |
dc.contributor.author | Langer C.J. | en_US |
dc.creator | Awad M.M.;Gadgeel S.M.;Borghaei H.;Patnaik A.;Chih-Hsin Yang;Powell S.F.;Gentzler R.D.;Martins R.G.;Stevenson J.P.;Altan M.;Jalal S.I.;Panwalkar A.;Gubens M.;Sequist L.V.;Saraf S.;Zhao B.;Piperdi B.;Langer C.J. | - |
dc.date.accessioned | 2021-04-23T05:56:26Z | - |
dc.date.available | 2021-04-23T05:56:26Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85093671121&doi=10.1016%2fj.jtho.2020.09.015&partnerID=40&md5=17dd463282c04b6c7ff32b6d4f56cbed | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/557700 | - |
dc.description.abstract | Introduction: In cohort G of KEYNOTE-021 (NCT02039674), first-line pembrolizumab plus pemetrexed-carboplatin significantly improved the objective response rate and progression-free survival versus chemotherapy alone with manageable toxicity in advanced nonsquamous NSCLC. We report the long-term outcomes from this study. Methods: Patients with previously untreated advanced nonsquamous NSCLC without sensitizing EGFR or ALK alterations were randomly assigned 1:1 to receive open-label pemetrexed 500 mg/m2 plus carboplatin at area under the concentration-time curve of 5 mg/mL/min (four cycles) with or without pembrolizumab 200 mg (up to 2 years), with optional pemetrexed maintenance, each administered every 3 weeks. Eligible patients could crossover from the chemotherapy arm to pembrolizumab monotherapy after progression. Responses were assessed per the Response Evaluation Criteria in Solid Tumors version 1.1. Results: After the median time of 49.4 months from randomization to data cutoff, objective response rate (58% versus 33%) and progression-free survival (median: 24.5 versus 9.9 mo; hazard ratio: 0.54; 95% confidence interval: 0.35?0.83) remained improved with pembrolizumab combination (n = 60) versus chemotherapy (n = 63), regardless of programmed death ligand 1 status. Median overall survival was 34.5 versus 21.1 months (hazard ratio: 0.71; 95% confidence interval: 0.45?1.12), despite a 70% crossover rate from chemotherapy alone to anti?programmed death (ligand) 1 therapy. Among the 12 patients who completed 2 years of pembrolizumab, 92% were alive at data cutoff; the estimated 3-year duration of response rate was 100%. Grade 3 to 5 treatment-related adverse events occurred in 39% of patients receiving pembrolizumab combination and 31% receiving chemotherapy. Conclusions: First-line pembrolizumab plus pemetrexed-carboplatin continued to show improved response and survival versus chemotherapy alone in advanced nonsquamous NSCLC, with durable clinical benefit in patients who completed 2 years of therapy. No new safety signals were observed with longer follow-up. ? 2020 International Association for the Study of Lung Cancer | - |
dc.publisher | Elsevier Inc. | - |
dc.relation.ispartof | Journal of Thoracic Oncology | - |
dc.subject | Advanced nonsquamous non?small-cell lung cancer; Chemotherapy; First-line therapy; Long-term survival; Pembrolizumab | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | carboplatin; pembrolizumab; pemetrexed; programmed death 1 ligand 1; antineoplastic agent; carboplatin; monoclonal antibody; pembrolizumab; pemetrexed; adult; advanced cancer; aged; ALK gene; area under the curve; Article; cancer chemotherapy; cancer growth; cohort analysis; controlled study; EGFR gene; female; gene; gene mutation; human; maintenance therapy; major clinical study; male; multiple cycle treatment; non small cell lung cancer; open study; overall survival; phase 2 clinical trial; priority journal; progression free survival; randomized controlled trial; treatment outcome; treatment response; unspecified side effect; lung tumor; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Lung Neoplasms; Pemetrexed | - |
dc.title | Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jtho.2020.09.015 | - |
dc.identifier.pmid | 33069888 | - |
dc.identifier.scopus | 2-s2.0-85093671121 | - |
dc.relation.pages | 162-168 | - |
dc.relation.journalvolume | 16 | - |
dc.relation.journalissue | 1 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。